netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Infliximab found 19 matches

Formulary items 3 matches
   
Open monograph to display formulary status BNF Category
  Infliximab  (Remicade®, Inflectra®, Remsima®) Gastro-intestinal system - Cytokine inhibitors - 01.05.03
  Infliximab  (Remsima®, Inflectra®, Remicade®) Skin - Drugs affecting the immune response - 13.05.03
  Infliximab  (Remsima®, Inflectra®, Remicade® ) Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Adalimumab and Infliximab for Children with Severe Refractory Uveitis (11.04.02)
link in drug section NHSE Specialised Commissioning Policy: Infliximab for refractory sarcoidosis (excluding neurosarcoidosis) (adults)  (10.01.03)
link in drug section NICE TA134: Infliximab for psoriasis (13.05.03)
link in drug section NICE TA163: Ulcerative colitis (acute manifestations) Infliximab (01.05.03)
link in drug section NICE TA187: Crohn’s disease - infliximab and adalimumab  (01.05.03)
link in drug section NICE TA187: Crohns disease - infliximab & adalimumab (01.05.03)
link in subsection NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
link in subsection NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
link in drug section NTAG recommends the use of infliximab biosimilars as an option where the originator product (Remicade®) would normally be prescribed (01.05.03)


 
netFormulary